Coherus Bio (CHRS) |
|
20.43 0.88 (4.5%)
|
01-27 02:17 |
|
Open: |
19.76 |
Pre. Close: |
19.55 |
|
High:
|
20.64 |
Low:
|
19.29 |
|
Volume:
|
1,639,869 |
Market Cap:
|
1,472M |
|
|
|
|
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.665 - 20.744 |
20.744 - 20.824 |
|
Low:
|
19.089 - 19.181 |
19.181 - 19.273 |
|
Close:
|
20.276 - 20.422 |
20.422 - 20.568 |
|
Technical analysis |
as of: 2021-01-26 4:42:14 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 24.11  One year: 28.16 |
| Support: |
Support1: 18.14 Support2: 16.60 |
| Resistance: |
Resistance1: 20.64 Resistance2: 24.11 |
| Pivot: |
18.05 |
| Moving Average: |
MA(5): 18.92 MA(20): 17.83
MA(100): 18.00 MA(250): 17.91 |
| MACD: |
MACD(12,26): 0.40 Signal(9): 0.11 |
| Stochastic oscillator: |
%K(14,3): 87.02 %D(3): 83.51 |
| RSI: |
RSI(14): 70.83 |
| 52-week: |
High: 23.03 Low: 10.86 Change(%): 8.8 |
| Average Vol(K): |
3-Month: 93364 10-Days: 126148 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.CHRS has closed above the upper band by 17.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 77.9% wider than normal. The large width of the bands suggest high volatility as compared to CHRS's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Mon, 21 Dec 2020
Coherus BioSciences Announces New Employment Inducement Grants - GlobeNewswire
Fri, 06 Nov 2020
Coherus BioSciences Inc (CHRS) Q3 2020 Earnings Call Transcript - Motley Fool
Thu, 05 Nov 2020
Coherus BioSciences Reports Third Quarter 2020 Financial Results - GlobeNewswire
Thu, 22 Oct 2020
Coherus BioSciences to Report Third Quarter Financial Results on November 5th - GlobeNewswire
Thu, 06 Aug 2020
Coherus BioSciences Reports Second Quarter 2020 Financial Results - GlobeNewswire
Mon, 03 Aug 2020
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
72 |
| Shares Float (M) |
60 |
|
% Held by Insiders
|
1.62 |
|
% Held by Institutions
|
125.64 |
|
Shares Short (K)
|
14,600 |
|
Shares Short P. Month (K)
|
15,760 |
Stock Financials |
|
EPS
|
2.050 |
|
EPS Est This Year
|
-5.130 |
|
EPS Est Next Year
|
-2.620 |
|
Book Value (p.s.)
|
3.550 |
|
Profit Margin
|
33.06 |
|
Operating Margin
|
37.82 |
|
Return on Assets (ttm)
|
20.5 |
|
Return on Equity (ttm)
|
103.8 |
|
Qtrly Rev. Growth
|
1.7 |
|
Gross Profit (p.s.)
|
3.399 |
|
Sales Per Share
|
6.791 |
|
EBITDA (p.s.)
|
2.611 |
|
Qtrly Earnings Growth
|
-40.60 |
|
Operating Cash Flow (M)
|
139 |
|
Levered Free Cash Flow (M)
|
52 |
Stock Valuations |
|
PE Ratio
|
9.97 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.75 |
|
Price to Sales
|
3.01 |
|
Price to Cash Flow
|
10.61 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
